Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Pembrolizumab & Cervical cancer, the FDA has approved single‑agent pembrolizumab for patients with recurrent or metastatic cervical cancer that has progressed on or after chemotherapy, whose tumors express PD‑L1 (CPS ≥1). This was initially accelerated in 2018 and later converted to regular approval (1).
In the treatment of advanced cervical cancer with PD-L1 expression, pembrolizumab could potentially become the preferred option, applicable in both metastatic and recurrent cases. Nonetheless, it is crucial to more accurately identify and …